NDA 217472 · Fresenius Kabi USA
Rocuronium Bromide
Rocuronium Bromide · Intravenous
Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jun 9, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
544
61 Phase 3, 36 recruiting
FAERS reports
12,125
11,055 serious, 968 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 2, 2026.
Rocuronium Bromide Injection is indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Rocuronium Bromide Injection is a nondepolarizing neuromuscular blocking agent indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. ( 1 )
Mechanism: Rocuronium Bromide Injection is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. It acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- ROCURONIUM BROMIDE · ROCURONIUM BROMIDE 50MG/5ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- ROCURONIUM BROMIDE · ROCURONIUM BROMIDE 100MG/10ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Rocuronium" as an intervention, any sponsor and status, largest first.
University of California, Los AngelesAcademic, hospital or other
NCT04263363 · 12,248 participants · Start Feb 18, 2022 · Primary completion May 7, 2024
Drug: Sugammadex 100 MG/ML [Bridion] · For: Respiratory Complication; Obstructive Sleep Apnea
Sites: Los Angeles, California
- A Study of Residual Curarization Incidence in ChinaPivotal-lookingStatus unknown
Peking University First HospitalAcademic, hospital or other
NCT01690338 · 6,090 participants (planned) · Start Oct 2012 · Primary completion Oct 2014
Drug: Vecuronium Bromide; Rocuronium and 1 more · For: Perioperative/Postoperative Complications; PORC (Postoperative Residual Curarization)
Sites: Beijing, China; Guangzhou, China; Shijiazhuang, China · 22 sites in all
- Remifentanil Versus Rocuronium for Optimizing Video Laryngoscopy-assisted Tracheal IntubationPivotal-lookingRecruiting
Nordsjaellands HospitalAcademic, hospital or other
NCT06564857 · 2,684 participants (planned) · Start Nov 17, 2025 · Primary completion Apr 1, 2027
Drug: Remifentanil; Rocuronium · For: Tracheal Intubation; Video Laryngoscopy; Remifentanil and 1 more
Sites: Copenhagen, Denmark; Hillerød, Denmark
- Succinylcholine vs Rocuronium for Prehospital Emergency IntubationPivotal-lookingCompleted
Centre Hospitalier Universitaire de la RéunionAcademic, hospital or other
NCT02000674 · 1,321 participants · Start Dec 2013 · Primary completion Jul 2016
Drug: Succinylcholine : 1mg/kg; Rocuronium : 1.2 mg/kg · For: Coma; Major Trauma; Respiratory Distress and 1 more
Sites: Saint-Denis, France; Saint-Pierre, France; Bobigny, France · 17 sites in all
- Impact of Anesthesia Maintenance Methods on 5-year Survival After SurgeryPivotal-lookingCompleted
Peking University First HospitalAcademic, hospital or other
NCT05343260 · 1,228 participants · Start Apr 1, 2015 · Primary completion Sep 30, 2022
Drug: Sevoflurane; Propofol · For: Aged; Neoplasms; Surgical Procedure, Operative and 3 more
Sites: Beijing, China; Nanning, China; Guiyang, China · 15 sites in all
- Impact of Anesthesia Maintenance Methods on Long-term SurvivalPivotal-lookingCompleted
Peking University First HospitalAcademic, hospital or other
NCT02660411 · 1,228 participants · Start Apr 1, 2015 · Primary completion Sep 29, 2017
Drug: Sevoflurane; Propofol · For: Aged; Neoplasms; Surgical Procedure, Operative and 3 more
Sites: Beijing, China; Nanning, China; Shenzhen, China · 17 sites in all
- Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01422304 · 1,198 participants · Start Oct 12, 2011 · Primary completion Sep 26, 2012
Drug: Sugammadex; neostigmine and glycopyrrolate or atropine and 2 more · For: Neuromuscular Blockade; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee and 2 more
- Assessment of Remifentanil for Rapid Sequence Induction and Intubation in Full Stomach Patient Compared to Muscle RelaxantPivotal-lookingCompleted
Nantes University HospitalAcademic, hospital or other
NCT03960801 · 1,150 participants · Start Oct 9, 2019 · Primary completion Apr 22, 2021
Drug: Remifentanil group; neuromuscular blockade group · For: Intra-tracheal Intubation
Sites: Angers, France; Brest, France; Grenoble, France · 13 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- anaphylactic reaction1,326
- hypotension1,158
- drug ineffective1,155
- anaphylactic shock1,073
- cardiac arrest685
- drug interaction476
- tachycardia435
- off label use428
- bradycardia404
- bronchospasm385
- rash297
- urticaria287
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 44 |
| 2005 | 86 |
| 2006 | 58 |
| 2007 | 59 |
| 2008 | 108 |
| 2009 | 180 |
| 2010 | 227 |
| 2011 | 302 |
| 2012 | 332 |
| 2013 | 263 |
| 2014 | 321 |
| 2015 | 322 |
| 2016 | 607 |
| 2017 | 491 |
| 2018 | 699 |
| 2019 | 853 |
| 2020 | 928 |
| 2021 | 873 |
| 2022 | 895 |
| 2023 | 985 |
| 2024 | 1,005 |
| 2025 | 1,137 |
| 2026 | 1,348 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Current · updated Nov 18, 2026
Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05). Check wholesalers for inventory
Current · updated Nov 18, 2026
Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-444-10). Check wholesalers for inventory
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparison of rocuronium priming vs. standard rapid sequence intubation technique in emergency department patients requiring intubation.
Işk N, Özhasenekler A, Yldrm Ç, et al. · Rev Assoc Med Bras (1992) 2024 · Randomized Controlled Trial, Comparative Study
- Rocuronium Continuous Infusion for Profound Neuromuscular Blockade: A Systematic Review and Meta-analysis.
Couto M, Nunes C, Vide S, et al. · Clin Neuropharmacol 2019 · Meta-Analysis, Systematic Review
- Study of Rocuronium-Sugammadex as an Alternative to Succinylcholine-Cisatracurium in Microlaryngeal Surgery.
Aragón-Benedí C, Visiedo-Sánchez S, Pascual-Bellosta A, et al. · Laryngoscope 2021 · Comparative Study, Randomized Controlled Trial
- Intubation conditions and neonatal outcomes with rocuronium versus suxamethonium in cesarean sections: A systematic review and meta-analysis.
Hassan AA, Khalafallah MA, Ismail NR, et al. · BMC Anesthesiol 2025 · Systematic Review, Meta-Analysis
- Comparison between rocuronium and succinylcholine for rapid sequence induction: A systematic review and network meta-analysis of randomized clinical trials.
de Carvalho CC, da Silva DM, de Athayde Regueira SLP, et al. · J Clin Anesth 2021 · Letter, Systematic Review
- Large vein injection alleviates rocuronium-induced pain in gynaecologic patients.
Zhang XM, Wang Q, Wang WS, et al. · Anaesth Crit Care Pain Med 2017 · Randomized Controlled Trial
Sponsor: Fresenius Kabi USA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.